204 related articles for article (PubMed ID: 30066356)
1. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
Takeda K; Komatsu K; Morita S
Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
Takeda K; Zhu J; Li R; Yamaguchi Y
Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
[TBL] [Abstract][Full Text] [Related]
3. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
4. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
5. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
Takeda K; Morita S
Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
[TBL] [Abstract][Full Text] [Related]
6. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
Li R; Takeda K; Rong A
Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
[TBL] [Abstract][Full Text] [Related]
7. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
Yang C; Li Y
Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
Janssen JM; Zwaan CM; Schellens JHM; Beijnen JH; Huitema ADR
Eur J Cancer; 2017 Nov; 85():78-85. PubMed ID: 28892776
[TBL] [Abstract][Full Text] [Related]
10. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
11. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.
Toumazi A; Comets E; Alberti C; Friede T; Lentz F; Stallard N; Zohar S; Ursino M
Comput Methods Programs Biomed; 2018 Apr; 157():163-177. PubMed ID: 29477425
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.
Ursino M; Zohar S; Lentz F; Alberti C; Friede T; Stallard N; Comets E
Biom J; 2017 Jul; 59(4):804-825. PubMed ID: 28321893
[TBL] [Abstract][Full Text] [Related]
13. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
14. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
15. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
[TBL] [Abstract][Full Text] [Related]
16. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
17. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
Takeda K; Morita S; Taguri M
Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
[TBL] [Abstract][Full Text] [Related]
18. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
19. An adaptive dose-finding design incorporating both toxicity and efficacy.
Zhang W; Sargent DJ; Mandrekar S
Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
[TBL] [Abstract][Full Text] [Related]
20. Improved designs for dose escalation studies using pharmacokinetic measurements.
Piantadosi S; Liu G
Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
